Go Home Egetis Therapeutics Logo
  • Healthcare Professionals
    • MCT8 deficiency
    • EMCITATE® (tiratricol)
    • Clinical Trials & Managed Access
    • Medical Information
Share price: Latest: (SEK) High: (SEK)
  • About us
    • Mission & Vision
    • Who We Are
    • Governance
      • General Meetings
      • Board of Directors
      • Leadership Team
      • Committees
      • Auditors
      • Corporate Governance Reports
      • Articles of Association
    • History & Milestones
    • Ethics, Integrity & Compliance
  • Science & Pipeline
    • Research Approach
    • Pipeline Overview
    • Resistance to Thyroid Hormone Beta (RTH-beta)
    • Clinical Trials
    • Publications & Data
    • Patents & Intellectual Property
  • Patient & Caregivers
    • Understand MCT8 Deficiency
    • Living with MCT8 / Patient Stories
    • Support
    • Educational Resources
  • Investors
    • The Share
      • Shareholders
      • Share capital development
      • Equity Issues
      • Stock Option Programs
      • Insider trading
    • Analysts
    • Report Archive
    • Calendar
    • IR-contact
    • Privacy Policy
  • News & Insights
    • Press releases
    • Latest From LinkedIn
  • Careers
    • Why Join Us
    • Culture & Values
    • Open Positions
  • Contact
    • Offices & Locations
    • Contact form
Home ▸ Investors Content ▸ Egetis Corporate Presentation February 2023

Egetis Corporate Presentation February 2023

February 23, 2023

Download Egetis Corporate Presentation February 2023
Share
Egetis Logo

We care for the rare

Rare Thyroid Therapeutics International is a wholly owned subsidiary of Egetis Therapeutics

Follow us on Go to Youtube Go to LinkedIn Go to Facebook Go to X
Useful links
  • About us
  • Science & Pipeline
  • Patient & Caregivers
  • Contact
More from us
  • News & Insights
  • Careers
  • Press releases
Investor
  • Investors
  • Reports & Presentations
  • The Share
  • IR-contact

© 2018-2026 Egetis Therapeutics. All rights reserved.

  • Privacy Notice
  • Cookie Settings
  • Cookie Policy
  • Sitemap
Skip to toolbar
  • About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
Go Home
  • Home
  • About us
    • About us
    • Mission & Vision
    • Who We Are
    • Governance
    • History & Milestones
    • Ethics, Integrity & Compliance
    • Governance
    • General Meetings
    • Board of Directors
    • Leadership Team
    • Committees
    • Auditors
    • Corporate Governance Reports
    • Articles of Association
  • Science & Pipeline
    • Science & Pipeline
    • Research Approach
    • Pipeline Overview
    • Resistance to Thyroid Hormone Beta (RTH-beta)
    • Clinical Trials
    • Publications & Data
    • Patents & Intellectual Property
  • Patient & Caregivers
    • Patient & Caregivers
    • Understand MCT8 Deficiency
    • Living with MCT8 / Patient Stories
    • Support
    • Educational Resources
  • Investors
    • Investors
    • The Share
    • Analysts
    • Report Archive
    • Calendar
    • IR-contact
    • Privacy Policy
    • The Share
    • Shareholders
    • Share capital development
    • Equity Issues
    • Stock Option Programs
    • Insider trading
  • News & Insights
    • News & Insights
    • Press releases
    • Latest From LinkedIn
  • Careers
    • Careers
    • Why Join Us
    • Culture & Values
    • Open Positions
  • Contact
    • Contact
    • Offices & Locations
    • Contact form
  • Healthcare Professionals
    • Healthcare Professionals
    • MCT8 deficiency
    • EMCITATE® (tiratricol)
    • Clinical Trials & Managed Access
    • Medical Information

Subscribe

Be the first to hear about news from Egetis

You are leaving our website

You're about to visit an external website. Egetis Therapeutics is not responsible for its content.